Symphogen Opens US Operations in Princeton, New Jersey

“This is the optimal time to strengthen Symphogen’s global presence as our novel pipeline is advancing into the later-stages of clinical development,” said Kirsten Drejer, Ph.D., CEO of Symphogen.

Ms. Sax added, “Antibody therapeutics and technologies continue to drive significant value for the pharmaceutical industry. New Jersey has long been recognized as good centralized location for bioscience companies with global development programs and multiple worldwide partnerships, so it was an easy decision for Symphogen to base our US business here. With Symphogen’s growing pipeline and leading antibody discovery and expression technologies, we are excited about the company’s future prospects and hope to capitalize on these opportunities by having broad access to physicians, patients and partners.”

About Symphogen

Symphogen is developing superior antibody therapeutics to help people with serious diseases. With its proprietary Symplex^TM discovery and Sympress^TM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease. Symphogen is a private biopharmaceutical company with more than 70 employees, and its headquarters are based in Copenhagen, Denmark. www.symphogen.com

Symphogen, Inc.
Kirsten Drejer, CEO, +45 45 26 50 59
+45 22 10 99 59 (cell)
kd@symphogen.com
or
Media:
Karen Miller, Manager, +1-609-951 2295
US Business Operations
kmi@symphogen.com